Ebola: a study in Guinea reveals persistent immunity five years after vaccination

 

Paris, le 5 septembre 2024

 

Press information

 

 

Epidemics of Ebola virus disease occur periodically in several sub-Saharan African countries. Two vaccines have already received WHO prequalification against the Ebolavirus Zaire species. However, information on the long-term immune response to these vaccines is still insufficient. We need to consolidate our knowledge on this subject to continue developing the safest and most effective vaccination strategies possible, for both adults and children. In a new study conducted in Guinea, scientists from VRI, Inserm and Université Paris-Est Créteil (U955 Institut Mondor de recherche biomédicale) have taken a further step in this direction. They have shown that the cellular immune response induced by three different vaccine strategies is maintained for up to five years after vaccination. These results, which support current vaccine strategies against Ebola, are published in Nature Communications.

The Ebola virus causes high fevers and hemorrhages, often resulting in death. Many countries in sub-Saharan Africa regularly face epidemic outbreaks. the Ebola virus caused the largest epidemic known to date in West Africa in 2014. It has since re-emerged several times in the DRC, but also in Guinea. Vaccination is today one of the most effective tools for combating the disease, and one of the major challenges for research and public health strategy is to continue improving knowledge of the immune response induced in the long term by currently available vaccines.

Since 2019, two vaccines have obtained WHO prequalification against the Ebolavirus Zaire strain: the rVSVΔG-ZEBOV-GP vaccine (Ervebo®), developed by Merck, Sharpe & Dohme, Corp. and the vaccine regimen comprising Johnson & Johnson’s Ad26.ZEBOV (Zabdeno®) vaccine and Bavarian Nordic’s MVA-BN-Filo (Mvabea®) vaccine.

In 2022, the international PREVAC consortium (see box at the end), comprising Inserm, NIH and the London School of Hygiene and Tropical Medicine (LSHTM), published a study in the New England Journal of Medicine examining the safety and efficacy of three vaccine regimens:
• The first vaccine regimen tested consisted of one dose of Ad26.ZEBOV vaccine, followed 56 days later by one dose of MVA-BN-Filo;
• The second regimen involved a dose of rVSVΔG-ZEBOV-GP;
• Finally, the third schedule began with a dose of rVSVΔG-ZEBOV-GP, followed 56 days later by a booster dose of the same vaccine.

Published results showed a high serum antibody response 12 months after vaccination. However, it was essential to obtain information on the long-term maintenance of the response, and in particular regarding the cellular response (see box below).

 

Humoral response and cellular response   Adaptive immune responses fall into two broad categories: the humoral response, based on the production of antibodies, by B lymphocytes, that recognize and neutralize the virus before it infects cells, and the cellular response, where CD8+ T lymphocytes identify and destroy already-infected cells to limit the spread of the virus. CD4+ T lymphocytes play a crucial role in helping B lymphocytes produce antibodies, boosting the effectiveness of the immune response. In this study, scientists looked specifically at the short-, medium- and long-term (5 years) cellular response in participants following vaccination with three different vaccine regimens.

 

In December 2023, the 5-year follow-up of participants in the PREVAC clinical trial was completed. The results are being analyzed and will enable assessment of long-term immunity. sIn an ancillary study, scientists analyzed cellular immunity in 230 participants in Guinea, just after vaccination, at one year and five years post-vaccination.

“This is the first study from the PREVAC consortium to look specifically at participants’ cellular immune response. It completes the knowledge already acquired on the humoral response at one year and offers the first follow-up results at 5 years”, emphasizes Aurélie Wiedemann, immunologist at VRI and the Institut Mondor de recherche biomédicale (Inserm/Université Paris Est Créteil) and first author of the study.

Using blood samples taken in Conakry, the scientists were able to analyze the response of CD4+ and CD8+ T lymphocytes to vaccination. They showed the presence of anti-Ebola CD4+ T cells five years after vaccination, regardless of the vaccination regimen. The persistence of these responses is important for the maintenance of humoral immune memory in the event of exposure to the Ebola virus. In a subgroup of volunteers, the authors show a correlation between CD4+ T cell response and the quantity of specific antibodies in the long term.

While CD4+ T response is important for maintaining an antibody response, the presence of cytotoxic CD8+ T cells is also crucial for effective antiviral protection. A specific CD8+ T cell response was demonstrated in individuals vaccinated with two of the three vaccine regimens.

“These results will shortly be supplemented by humoral response data – on antibody production – from all PREVAC consortium countries, on a larger number of participants. Nevertheless, these results are promising and suggest that vaccination against the Ebola virus can induce long lasting immunity. They also pave the way for adjusting current vaccination strategies, by making it possible to assess, for example, the need for a long-term booster vaccination”, explains Prof. Yves Lévy, Director of the VRI and final author of the study.

In 2020, the team also published a study in Nature Communications on the immunity of Ebola survivors two years after discharge from hospital. One of the next avenues of research could be to compare the long-term immune response of these survivors with that induced by vaccination, in order to identify possible correlates of protection against infection, as these are currently undetermined.

Thus, this new study could help identify vaccine responses that would be effective against the infection, improve current vaccine strategies, and define long-term booster vaccine strategies to maintain protection for particularly at-risk individuals such as healthcare workers in Africa.

 

About PREVAC   PREVAC (Partnership for Research on Ebola Vaccinations; NCT02876328) is an international consortium conducting researches in West Africa to evaluate the safety and efficacy of Ebola vaccination. The project is co-funded by Inserm, NIAID, the London School of Hygiene & Tropical Medicine (LSHTM) and the College of Medicine and Allied Health Sciences (Comahs), with support from Guinea, Liberia, Mali and Sierra Leone. On-the-ground support from the NGO Alima was also crucial in encouraging the population to take part in the research and in monitoring the volunteers. Manufacturers Merck and Janssen supplied the vaccines used in the trial. The project also benefited from additional funding to continue long-term follow-up of volunteers (PREVAC-UP project coordinated by Inserm) via the European and Developing Countries Clinical Trials Partnership (EDCTP2) program supported by the European Union.

 

 

 

 

Notes

 

 

Sources

 

Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases

Aurélie Wiedemann^1,2¥, Edouard Lhomme^1,3,4¥ Mélanie Huchon^1,4, Emile Foucat^1,2, Marion Bérerd-Camara⁵, Lydia Guillaumat^1,2, Marcel Yaradouno⁵, Jacqueline Tambalou⁵, Cécile Rodrigues^1,2, Alexandre Ribeiro^1,2, Abdoul Habib Béavogui⁶, Christine Lacabaratz^1,2, Rodolphe Thiébaut^1,3,4, Laura Richert^1,3,4, Yves Lévy^1,2,7*, and the Prevac study teama

1. Vaccine Research Institute, Université Paris-Est Créteil, France
2. INSERM U955, Institut Mondor de Recherche Biomedicale (IMRB), Team Lévy, Créteil, France
3. Univ. Bordeaux, INSERM, Institut Bergonié, CHU de Bordeaux, CIC-EC 1401, Euclid/F-CRIN clinical trials platform, Bordeaux, France
4. Univ. Bordeaux, Inserm, Population Health Research Center, UMR 1219, INRIA SISTM, Bordeaux, France
5. Alliance for International Medical Action
6. Centre National de Formation et de Recherche en Santé Rurale (CNFRSR), Maferinyah, Guinea
7. Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service Immunologie Clinique, Créteil, France

 

Researcher contact

 

Yves Lévy
Institut Mondor de Recherche Biomédicale (U955 Inserm/Université Paris-Est Créteil)
Vaccine Research Institute (VRI)
E-mail : yves.levy@inserm.fr

 

Aurélie Wiedemann
Institut Mondor de Recherche Biomédicale (U955 Inserm/Université Paris-Est Créteil)
Vaccine Research Institute (VRI)
E-mail : aurelie.wiedemann@inserm.fr
Téléphones sur demande

 

Contact presse

 

presse@inserm.fr
Accéder à la salle de presse de l’Inserm